focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Shaftesbury Down 13% Amid Fundraise Plans

Thu, 22nd Oct 2020 11:06

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

----------

FTSE 250 - LOSERS

----------

Shaftesbury, down 13%, and Capital & Counties, down 11%. Shaftesbury said it intends to raise GBP307 million via the issue of new shares to ensure financial flexibility to navigate the "unprecedented" challenges created by the Covid-19 pandemic. Current market capitalisation is GBP1.33 billion. Capital & Counties Properties said it will participate in the Shaftesbury fundraise by providing GBP65 million.

----------

Moneysupermarket, down 5.7%, the price comparison website firm said revenue dropped across all of its businesses in the third quarter, with the company blaming the "disruption" caused by the pandemic. In the three months to September 30, Moneysupermarket's total revenue dropped 16% year on year to GBP85.1 million.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Premier African Minerals up 19%. The southern Africa-focused miner said it has settled all amounts it owes to directors, employees and other creditors, amounting to GBP600,057 of shares. Along with the GBP1.1 million placing, completed on Wednesday, the company is now debt free.

----------

OPG Power Ventures, up 16%. The Indian power plant operator said revenue in the year ended March 31 rose 9.5% to GBP154.0 million from GBP140.6 million. Pretax profit slipped 14% to GBP14.5 million from GBP16.9 million.

----------

4D Pharma up 16% after it proposed a merger with special-purpose acquisition company Longevity Acquisition Corp. Longevity shareholders will hold 13% of the enlarged firm. The deal values 4D Pharma shares at GBP1.10 each - an 18% premium to its GBP0.932 closing price on Wednesday - GBP144.5 million altogether. 4D's current market capitalisation is GBP141.1 million. The enlarged company will also launch an American depositary receipts programme, eyeing a Nasdaq listing.

----------

Pendragon up 12%, the motor retailer said it delivered a "very strong" third quarter, with total revenue down 14% annually, but up 1.2% like-for-like. Underlying pretax profit surged to GBP27.3 million from GBP3.0 million a year earlier. Opts not to reinstate annual guidance, however.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Kibo Energy, down 12% after the Africa-focused energy firm posted a narrowed loss in the six months to June 30. Its pretax loss slimmed to GBP1.3 million from GBP1.8 million, though like last year, it generated no revenue. Noted that Covid-19 has caused delays to its project development targets.

----------

Thalassa Holdings, dropped 12% after a regulatory filing showed investor Lombard Odier Asset Management Ltd trimmed its stake in the British Virgin Islands-based investment holding company to 1.4% from 14% during a transaction on Wednesday.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
2 Feb 2015 16:06

UK AGM, EGM Calendar - Week Ahead

Read more
21 Jan 2015 08:51

4D Pharma Raises GBP34.8 Million Through Share Placing (ALLISS)

Read more
23 Sep 2014 12:24

4d Pharma Posts First-Half Loss, Says Pipeline Is Strong

Read more
2 Sep 2014 10:21

4D pharma progresses with IBS and Crohn's treatments

4D pharma has announced that its treatments for Irritable Bowel Syndrome (IBS) and Paediatric Crohn's Disease (PCD) are expected to enter clinical studies in the second quarter of 2015. The studies, which will be focused on evaluating safety and tolerability of the products as well as some clinica

Read more
2 Sep 2014 07:26

UK MORNING BRIEFING: Weir Group Leads Firm London Market On Upgrade

Read more
2 Sep 2014 06:55

4d Pharma's Blautix, Thetanix To Start Clinical Studies In 2015

Read more
7 Aug 2014 08:28

4d Pharma Gets Orphan Drug Designation From US FDA

Read more
7 Aug 2014 07:32

UK MORNING BRIEFING: Old Mutual, Coca-Cola HBC And RSA Weigh On FTSE

Read more
18 Jul 2014 10:00

4d Pharma Buys Microbiota For GBP2.0 Million

Read more
18 Jul 2014 07:25

UK MORNING BRIEFING: Shares Lower On Ukraine Crash, Gaza Offensive

Read more
25 Jun 2014 10:11

4d Pharma Raises GBP21.5 Million In Share Placing

Read more
25 Jun 2014 07:40

UK MORNING BRIEFING: Shares Down; Land Securities Buys Into Bluewater

Read more
4 Jun 2014 10:17

4d Pharma Raises Stake In GT Biologics To 83.5%

LONDON (Alliance News) - 4d Pharma PLC Wednesday said it has acquired a further 37.5% stake in GT Biologics Ltd for GBP1.22 million in new 4d Pharma shares, taking its total shareholding in the GT Biologics to 83.5%. 4d Pharma, which focuses on significant new therapeutic areas, said the ac

Read more
4 Jun 2014 07:53

4d pharma increases stake in GT Biologics to nearly 84%

4d pharma, an AIM-listed pharmaceutical company focused on new therapeutic areas, has added an additional 37.5% to its stake in GT Biologics taking its current holding to around 83.5%. The £1.22m consideration was satisfied by the issue of 699,500 new 4d shares at 175p each, reflecting their avera

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.